Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 75 (10), 1059-70

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

Affiliations
Review

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions

Laird Cameron et al. Drugs.

Abstract

Rearrangements of the anaplastic lymphoma kinase (ALK) gene originally discovered nearly 20 years ago in the context of anaplastic large cell lymphoma were identified as oncogenic drivers in a subset of non-small cell lung cancers (NSCLCs) in 2007. These ALK gene rearrangements are present in 3-5 % of NSCLC patients, typically younger, never or light smokers with adenocarcinomas. Crizotinib is a first-in-class ALK tyrosine kinase inhibitor with significant activity in ALK-positive NSCLC that received accelerated US Food and Drug Administration approval for treatment of ALK-positive NSCLC in 2011, just 4 years after identification of ALK rearrangements in this setting. Subsequently, two phase III trials have shown crizotinib to have a tolerable toxicity profile and to be superior to standard chemotherapy for the first- or second-line treatment of advanced ALK-positive lung cancer and numerous countries have approved its use. Despite initial responses, acquired resistance to crizotinib invariably leads to disease progression. Mechanisms of resistance have been described to include ALK tyrosine kinase mutations, activation of bypass signalling pathways and pharmacokinetic failure of crizotinib. Several next-generation ALK inhibitors, including ceritinib and alectinib, are in clinical development and show efficacy in both the crizotinib naïve and crizotinib refractory settings. Ongoing clinical trials will identify the optimal strategy to incorporate these novel agents in the treatment of patients with ALK-positive NSCLC.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Lancet Oncol. 2012 Oct;13(10):1011-9 - PubMed
    1. Mol Cancer Ther. 2014 Dec;13(12 ):2910-8 - PubMed
    1. Br J Cancer. 2012 Mar 13;106(6):1100-6 - PubMed
    1. Cancer Discov. 2013 Apr;3(4):430-43 - PubMed
    1. J Med Chem. 2014 Jun 12;57(11):4720-44 - PubMed

MeSH terms

Feedback